Summary
We performed a longitudinal follow-up study of clinical findings in 151 patients with high-titer antibodies against U1 ribonucleoprotein (U1RNP) as measured by haemagglutination. Formal connective tissue disease (CTD) diagnoses were assigned and diagnostic transitions analysed.
One-hundred eighteen females and 33 males entered the study; the mean duration of follow-up was 7.1 years. Mean age at entry was 34.7 years; 73% of the patients had early disease (duration <2 years). Fifty-six patients (37%) presented with a definite diagnosis, most often mixed connective tissue disease (MCTD, n=40), followed by systemic lupus erythematosus (SLE, n=11) and systemic sclerosis (SSc, n=5). Of 84 patients (56%) presenting with nonspecific symptoms of possible, “undifferentiated” CTD, 58 developed MCTD, 4 SSc and 2 SLE. By the end of the follow-up period, 127 patients had developed a well-defined CTD; final diagnoses were: MCTD (n=97), SLE (n=18), SSc (n=12).
We conclude that CTD in the context of high-titer anti-U1RNP antibodies may be transitive and sequential in nature, although the diagnostic criteria for MCTD previously proposed by our group seem to delimit a clinically stable condition in most patients in this subgroup.
Similar content being viewed by others
References
Sharp, G.C., Irvin, W.S., Tan, E.M., Gould, R.G., Holman, H.R. Mixed connective tissue disease — an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 1972, 52, 148–159.
Bennett, R.M. Scleroderma overlap syndromes. Rheum Dis Clin North Am 1990, 16, 185–198.
Bennett, R.M. Mixed connective tissue disease and other overlap syndromes. In: Textbook of Rheumatology, 3rd ed., Eds.: Kelley, W.N., Harris, E.D. Jr., Ruddy, S., Sledge, C.B., Philadelphia, Saunders, 1989, 1147–1165.
Sharp, G.C., Irvin, W.S., May, C.M., Holman, H.R., McDuffie, F.C., Hess, E.V., Schmid, F.R. Association of antibodies to ribonucleoprotein and Sm antigens with mixed connective tissue disease, systemic lupus erythematosus and other rheumatic diseases. N Engl J Med 1976, 295, 1149–1154.
Grennan, D.M., Bunn, C., Hughes, G.R.V., Buchanan, W.W., Dick, W.C. Frequency and clinical significance of antibodies to ribonucleoprotein in SLE and other connective tissue disease subgroups. Ann Rheum Dis 1977, 36, 442–447.
Maddison, P.J., Mogavero, H., Reichlin, M. Patterns of clinical disease associated with antibodies to nuclear ribonucleoprotein. J Rheumatol 1978, 5, 407–411.
Gaudreau, A., Amor, B., Kahn, M. Clinical significance of antibodies to soluble extractable nuclear antigens (anti-ENA). Ann Rheum Dis 1978, 37, 321–327.
Bennett, R.M., O'Connell, D.J. Mixed connective tissue disease: a clinicopathologic study of 20 cases. Semin Arthritis Rheum 1980, 10, 25–51.
Grant, K.D., Adams, L.E., Hess, E.V. Mixed connective tissue disease — a subset with sequential clinical and laboratory features. J Rheumatol 1981, 8, 587–598.
Hochberg, M.C., Dorsch, C.A., Feinglass, E.J., Stevens, M.B. Survivorship in systemic lupus erythematosus: effect of antibody to extractable nuclear antigen. Arthritis Rheum 1981, 24, 54–59.
Lemmer, J.P., Curry, N.H., Mallory, J.H., Waller, M.V. Clinical characteristics and course in patients with high titer anti-RNP antibodies. J Rheumatol 1982, 9, 536–542.
Leibfarth, J.H., Persellin, R.H. Characteristics of patients with serum antibodies to extractable nuclear antigens. Arthritis Rheum 1976, 19, 851–856.
Rasmussen, E.K., Ullman, S., Høier-Madsen, M., Sørensen, S.F., Halberg, P. Clinical implications of ribonucleoprotein antibody. Arch Dermatol 1987, 123, 601–605.
Calderon, J., Rodriguez-Valverde, V., Sanchez Andrade, S., Riestra, J.L., Gomez-Reyno, J. Clinical profiles of patients with antibodies to nuclear ribonucleoprotein. Clin Rheumatol 1984, 3, 483–492.
Combe, B., Rucheton, M., Graafland, H., Lussiez, V., Brunel, C., Sany, J. Clinical significance of anti-RNP and anti-Sm autoantibodies as determined by immunoblotting and immunoprecipitation in sera from patients with connective tissue diseases. Clin Exp Immunol 1989, 75, 18–24.
Lundberg, I., Nyman, U., Pettersson, I., Hedfors, E. Clinical manifestations and anti-(U1)snRNP antibodies: a prospective study of 29 anti-RNP antibody positive patients. Br J Rheumatol 1992, 31, 811–817.
Nimelstein, S.H., Brody, S., McShane, D., Holman, H.R. Mixed connective tissue disease: a subsequent evaluation of the original 25 patients. Medicine 1980, 59, 239–248.
ter Borg, E.J., Groen, H., Horst, G., Limburg, P.C., Wouda, A.A., Kallenberg, C.G. Clinical associations of antiribonucleoprotein antibodies in patients with systemic lupus erythematosus. Semin Arthritis Rheum 1990, 20, 164–173.
Reichlin, M., van Venrooij, W.J. Autoantibodies to the URNP particles: relationship to clinical diagnosis and nephritis. Clin Exp Immunol 1991, 83, 286–290.
De Clerck, L.S., Meijers, K.A., Cats, A. Is MCTD a distinct entity? Comparison of clinical and laboratory findings in MCTD, SLE, PSS, and RA patients. Clin Rheumatol 1989, 8, 29–36.
Lundberg, I., Hedfors, E. Clinical course of patients with anti-RNP antibodies. A prospective study of 32 patients. J Rheumatol 1991, 18, 1511–1519.
Sullivan, W.D., Hurst, D.J., Harmon, C.E., Esther, J.H., Agia, G.A., Maltby, J.D., Lillard, S.B., Held, C.N., Wolfe, J.F., Sunderrajan, E.V., Maricq, H.R., Sharp, G.C. A prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease. Medicine 1984, 63, 92–107.
Tiddens, H.A., van der Net, J.J., de Graeff Meeder, E.R., Fiselier, T.J., de Rooij, D.J., van Luijk, W.H., Herzberger, R., van Suijlekom, L.W., van Venrooij, W.J., Zegers, B.J., et al, Juvenile-onset mixed connective tissue disease: longitudinal follow-up. J Pediatr 1993, 122, 191–197.
Tan, E.M., Cohen, A.S., Fries, J.F. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25, 1271–1277.
Masi, A.T., Rodnan, G.P., Medsger, T.A. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Bull Rheum Dis 1981, 31, 1–6.
Bohan, A., Peter, J.B. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975, 292, 344–347.
Høier-Madsen, M., Andersen, M.G. Microhaemagglutinationstest til undersøgelse for antistoffer mod extractable nuclear antigen (ENA). Ugeskr Laeger 1980, 142, 2627–2630.
Sharp, G.C., Irvin, W.S., LaRoque, R.L., Velez, C., Kaiser, A.D., Holman, H.R. Association of autoantibodies to different nuclear antigens with clinical patterns of rheumatic disease and responsiveness to therapy. J Clin Invest 1971, 50, 350–359.
Alarcon-Segovia, D., Villareal, M. Classification and diagnostic criteria for mixed connective tissue disease. In: Mixed Connective Tissue Disease and Anti-nuclear Antibodies. Proceedings of the International Symposium on Mixed Connective Tissue Disease and Anti-nuclear Antibodies, Tokyo, 29–30 August 1986, Eds.: Kasukawa, R., Sharp, G.C., Amsterdam, Elsevier, 1987, 33–40.
Sharp, G.C. Diagnostic criteria for classification of MCTD. In: Mixed Connective Tissue Disease and Anti-nuclear Antibodies. Proceedings of the International Symposium on Mixed Connective Tissue Disease and Anti-nuclear Antibodies, Tokyo, 29–30 August 1986, Eds.: Kasukawa, R., Sharp, G.C., Amsterdam, Elsevier, 1987, 23–32.
Kasukawa, R., Tojo, T., Miyawaki, S., Yoshida, H., Tanimoto, K., Nobunaga, M., Suzuki, T., Takasaki, Y., Tamura, T. Preliminary diagnostic criteria for classification of mixed connective tissue disease. In: Mixed Connective Tissue Disease and Anti-nuclear Antibodies. Proceedings of the International Symposium on Mixed Connective Tissue Disease and Anti-nuclear Antibodies, Tokyo, 29–30 August 1986, Eds.: Kasukawa, R., Sharp, G.C., Amsterdam, Elsevier, 1987, 41–47.
Black, C., Isenberg, D.A. Mixed connective tissue disease-goodbye to all that. Br J Rheumatol 1992, 31, 695–700.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Frandsen, P.B., Kriegbaum, N.J., Ullman, S. et al. Follow-up of 151 patients with high-titer U1RNP antibodies. Clin Rheumatol 15, 254–260 (1996). https://doi.org/10.1007/BF02229703
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02229703